AN2 Therapeutics (ANTX) Total Non-Current Liabilities (2024 - 2026)

AN2 Therapeutics (ANTX) has reported Total Non-Current Liabilities for 3 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (changed N/A YoY), while the FY2025 annual figure was $8.7 million, down 14.83% from the prior year.
• Total Non-Current Liabilities slipped to $5.6 million in Q1 2026 per ANTX's latest filing, from $8.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $10.2 million in Q4 2024 and bottomed at $5.6 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $8.2 million across 3 years, with a median of $8.7 million in 2025.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 14.83% in 2025 and fell as far as 14.83% in 2025.
• AN2 Therapeutics' Total Non-Current Liabilities stood at $10.2 million in 2024, then fell by 14.83% to $8.7 million in 2025, then plunged by 36.22% to $5.6 million in 2026.
• Business Quant data shows ANTX's Total Non-Current Liabilities at $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $10.2 million in Q4 2024.